Pharmacology News and Research

Latest Pharmacology News and Research

Mimetogen Pharmaceuticals completes its equity financing

Mimetogen Pharmaceuticals Inc. ("Mimetogen"), a privately held drug development company announced today that it has successfully completed an equity financing, co-led by Boston-based VIMAC Milestone Medica Fund and Montréal-based iNovia Capital.

8 Oct 2009

Researchers reveal that H2 Blocker drugs pose no significant risks for the fetus

H2 Blocker drugs, such as Famotidine, Cimetidine and Ranitidine, approved in the U.S. for acid reflux (heartburn), pose no significant risks for the fetus according to a large collaborative cohort study by researchers at Ben-Gurion University of the Negev.

8 Oct 2009

Obesity and diabetes-2 increase the risk of serious health problems and reduce quality of life

Over the last 10-20 years, the number of cases of obesity and diabetes-2 has risen dramatically. The WHO considers obesity-related illnesses to be one of the world's biggest health problems. Obesity and diabetes-2 do not just reduce the quality of life but also dramatically increase the risk of serious health problems, such as cardiovascular diseases.

8 Oct 2009

New study finds rare type of head and neck cancer caused by HPV

An increase in cases of a rare type of head and neck cancer appears to be linked to HPV, or human papillomavirus, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

8 Oct 2009

NEI awards Case Western Reserve $1.57M for bacterial keratitis research

Researchers at Case Western Reserve University School of Medicine have been awarded a $1.57 million renewal grant from the National Eye Institute (NEI) of the National Institutes of Health to continue their study of corneal infections, specifically, bacterial keratitis, associated with contact lens wear. The grant will extend the work initiated last year with the receipt of a $2.4 million, five-year grant from the NEI.

8 Oct 2009

Research study to determine association of CYP2D6 variation with tamoxifen therapy

Among women with early stage breast cancer, genetic variation of a certain enzyme appears to be associated with clinical outcomes for women treated with tamoxifen, according to a study in the October 7 issue of JAMA.

7 Oct 2009

Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha-2b and L-DOS47 fruitful

Helix BioPharma Corp. today announced progress updates for its ongoing Topical Interferon Alpha-2b and L-DOS47 product development programs following pre-investigational new drug ("pre-IND") meetings with the U.S. Food and Drug Administration ("FDA").

7 Oct 2009

Misuse of aspirin might have caused high death rate during 1918-1919 influenza pandemic

The devastation of the 1918-1919 influenza pandemic is well known, but a new article suggests a surprising factor in the high death toll: the misuse of aspirin. Appearing in the November 1 issue of Clinical Infectious Diseases and available online now, the article sounds a cautionary note as present day concerns about the novel H1N1 virus run high.

3 Oct 2009

Increase in omega-3 fatty acid levels can prevent strokes, according to research

Research led by Hernan A. Bazan, MD, Assistant Professor of Surgery, Section of Vascular Surgery, at LSU Health Sciences Center New Orleans School of Medicine, has found that unstable carotid artery plaques - those in danger of rupturing and leading to a stroke - contain more inflammation and significantly less omega-3 fatty acids than asymptomatic plaques.

3 Oct 2009

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

Halozyme Therapeutics, Inc. today announced additional Phase 2 results that demonstrated faster insulin absorption and increased peak insulin concentrations in type 1 diabetic patients after co-administration of its recombinant hyaluronidase enzyme (rHuPH20 or PH20) with Humulin® R (regular human insulin), a mealtime insulin.

1 Oct 2009

NIH awards $10.5 million grant for OCD treatment research

A new research center exploring the science underlying a potential new treatment for obsessive-compulsive disorder has been established at the University of Rochester Medical Center, thanks to a $10.5 million award from the National Institute of Mental Health.

1 Oct 2009

New drug combination releives neuropathic pain and improves sleep

People who suffer from debilitating neuropathic pain may get more relief and sleep better by combining two commonly-prescribed drugs.

1 Oct 2009

Post Baccalaureate Premedical Program to begin in January 2010

Keck Graduate Institute (KGI) has established a Post Baccalaureate Premedical Program (PBPM), scheduled to begin in January 2010, for those with an undergraduate degree in science or engineering who are interested in enhancing their skills before applying to medical school.

30 Sep 2009

New treatment for Alzheimer's disease may be in the offing

Oleocanthal, a naturally-occurring compound found in extra-virgin olive oil, alters the structure of neurotoxic proteins believed to contribute to the debilitating effects of Alzheimer's disease. This structural change impedes the proteins' ability to damage brain nerve cells.

30 Sep 2009

Halozyme Therapeutics announces Phase 1 clinical study to assess three insulin analogs

Halozyme Therapeutics, Inc. today announced the commencement of a Phase 1 clinical study that will assess the effects of three approved prandial (mealtime) insulin analogs administered with its proprietary rHuPH20 (PH20) hyaluronidase enzyme compared to each of the analogs alone. This randomized, three-way cross-over design, euglycemic clamp study will compare the postprandial pharmacokinetics (PK) and glucodynamics (GD) of the insulin analogs.

28 Sep 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

FDA grants accelerated approval for Allos Therapeutics’ FOLOTYN

Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYNTM (pralatrexate injection) for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

28 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

NDA submitted to the FDA for new osteoarthritis drug

NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.

25 Sep 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

Pharmacology News and Research

Latest Pharmacology News and Research

Mimetogen Pharmaceuticals completes its equity financing

Researchers reveal that H2 Blocker drugs pose no significant risks for the fetus

Obesity and diabetes-2 increase the risk of serious health problems and reduce quality of life

New study finds rare type of head and neck cancer caused by HPV

NEI awards Case Western Reserve $1.57M for bacterial keratitis research

Research study to determine association of CYP2D6 variation with tamoxifen therapy

Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha-2b and L-DOS47 fruitful

Misuse of aspirin might have caused high death rate during 1918-1919 influenza pandemic

Increase in omega-3 fatty acid levels can prevent strokes, according to research

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

NIH awards $10.5 million grant for OCD treatment research

New drug combination releives neuropathic pain and improves sleep

Post Baccalaureate Premedical Program to begin in January 2010

New treatment for Alzheimer's disease may be in the offing

Halozyme Therapeutics announces Phase 1 clinical study to assess three insulin analogs

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

FDA grants accelerated approval for Allos Therapeutics’ FOLOTYN

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

NDA submitted to the FDA for new osteoarthritis drug

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Pharmacology News and Research

Latest Pharmacology News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in